Premium
High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma
Author(s) -
Chenard MariePierre,
O'Siorain Liam,
Shering Stephen,
Rouyer Nicolas,
Lutz Yves,
Wolf Catherine,
Basset Paul,
Belloco JeanPierre,
Duffy Michael Joseph
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19961220)69:6<448::aid-ijc5>3.0.co;2-4
Subject(s) - breast cancer , immunohistochemistry , breast carcinoma , medicine , mammary gland , ductal carcinoma , carcinoma , oncology , tumor progression , cancer , pathology , biology
Stromelysin 3 (ST3) is a matrix metalloprotease (MMP) expressed in fibroblast‐like cells of most human invasive carcinomas. In this investigation, ST3 was measured by semiquantitative immunohistochemistry in III primary breast cancers. ST3 levels showed no correlation with tumor size, axillary‐node status or tumor grade (Scarff‐Bloom‐Richardson system; SBR) but were significantly associated with higher nuclear grade (modified SBR). In addition, ST3 levels were significantly higher in ductal than in lobular cancers. Patients with high scores of ST3 staining had a shorter disease‐free interval and shorter overall survival than patients with low scores. ST3 is thus one of the first MMPs to correlate with patient outcome in breast cancer. These findings are consistent with earlier clinical and experimental observations suggesting that ST3 contributes to breast‐cancer progression. © 1996 Wiley‐Liss, Inc.